Carlos Luis Lopez - 19 Feb 2026 Form 4 Insider Report for Niagen Bioscience, Inc. (NAGE)

Reporting relationship: SVP, General Counsel
Issuer ticker: NAGE
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2026, 16:47:28 UTC
Prior SEC filing: 10 Mar 2025
Next SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeong James Lee, Attorney-in-Fact

Key filing fact

Carlos Luis Lopez filed Form 4 for Niagen Bioscience, Inc. (NAGE) on 24 Feb 2026.

Key facts

This page summarizes Carlos Luis Lopez's Form 4 filing for Niagen Bioscience, Inc. (NAGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 16:47.

Change

Previous filing in this sequence was filed on 10 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002042509 Primary reporting owner

Lopez Carlos Luis

Relationship: SVP, General Counsel
Address: 10900 WILSHIRE BLVD. SUITE 600, LOS ANGELES
Signature: /s/ Jeong James Lee, Attorney-in-Fact
Signature date: 24 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NAGE transaction Derivative

Employee Stock Options (right to buy)

Award

Transaction value: $0
Shares: +41,420
Change %
Price: $0.000000
Shares after: 41,420
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,420
Exercise price: $4.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .